Wednesday, July 8, 2026

pharma · Alzheimer Disease · Amyotrophic Lateral Sclerosis · AMLX

Amylyx Pharmaceuticals EMEA

Amylyx Pharmaceuticals EMEA clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Cambridge, USA HQ
167 Employees
Public company Type
AMLX · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Employees
167
Programs
7
Drugs
2
Patents
9
Intelligence · Clinical Programs

Amylyx Pharmaceuticals EMEA projects

1 ClinicalTrials.gov programs sponsored by Amylyx Pharmaceuticals EMEA.

Amylyx Pharmaceuticals EMEA has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AMX0114

    Amylyx Pharmaceuticals EMEA B.V.

    ALS

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Amylyx Pharmaceuticals EMEA have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.